Skip to main content Back to Top
Advertisement

5/11/2025

Morphine Sulfate Immediate-Release Tablets

Products Affected - Description

    • Morphine tablet, Hikma, 15 mg, bottle, 100 count, NDC 00054-0235-25
    • Morphine tablet, Hikma, 15 mg, unit-dose blister pack, 100 count, NDC 00054-0235-24
    • Morphine tablet, Hikma, 30 mg, bottle, 100 count, NDC 00054-0236-25
    • Morphine tablet, Hikma, 30 mg, unit-dose blister pack, 100 count, NDC 00054-0236-24
    • Morphine tablet, SpecGX (Mallinckrodt), 15 mg, bottle, 100 count, NDC 00406-5118-01
    • Morphine tablet, SpecGX (Mallinckrodt), 15 mg, unit-dose blister pack, 100 count, NDC 00406-5118-62
    • Morphine tablet, SpecGX (Mallinckrodt), 30 mg, bottle, 100 count, NDC 00406-5119-01
    • Morphine tablet, SpecGX (Mallinckrodt), 30 mg, unit-dose blister pack, 100 count, NDC 00406-5119-62
    • Morphine tablet, Upsher-Smith, 15 mg, bottle, 100 count, NDC 00832-0273-11 - discontinued
    • Morphine tablet, Upsher-Smith, 30 mg, bottle, 100 count, NDC 00832-0274-11 - discontinued

Reason for the Shortage

    • Ascend launched morphine 15 mg and 30 mg immediate-release tablets in May 2025.
    • Hikma did not provide a reason for the shortage.
    • SpecGX has not provided us with availability information.
    • Upsher-Smith is discontinuing morphine immediate-release tablets.

Available Products

    • Morphine tablet, Ascend, 15 mg, bottle, 100 count, NDC 67877-0670-01
    • Morphine tablet, Ascend, 30 mg, bottle, 100 count, NDC 67877-0671-01

Estimated Resupply Dates

    • Hikma has morphine 15 mg immediate-release tablets in 100 count unit-dose packages on back order and the company estimates a release date in early-July 2025. All other presentations are on allocation.

Updated

Updated May 11, 2025 by Elyse MacDonald, PharmD, MS, BCPS. Created April 6, 2025 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2025, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.
ADVERTISEMENT